at the World Society for Pediatric Infectious Diseases (WSPID) 14th Annual Congress on October 29, 2025.2Takeda plans to share results from additional non-endemic booster studies at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Congress on November 11, 2025.

About the Phase 3 TIDES (DEN-301) Trial

The double-blind, randomized, placebo-controlled Phase 3 TIDES trial evaluated the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in more than 20,000 healthy children and adolescents 4-16 years of age.3Study participants were randomized 2:1 to receive two doses of TAK-003 0.5 mL or placebo on months 0 and 3, administered subcutaneously.3The study is comprised of five parts. Part 1 and the primary endpoint analysis evaluated VE and safety through 12 months after the second dose.3Part 2 continued for an additional six month
=*=*=*=*=*=
当前为第5/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页